Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 13/20 | 1.00 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAT2A | P31153 | 2/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14991999 | 1.00 | CYP11B2 (1.00) | CYP11B2CYP11B1TSHRALDH1A1MAT2A | |
| SCHEMBL14991998 | 1.00 | CYP11B2 (1.00) | CYP11B2CYP11B1TSHRALDH1A1MAT2A | |
| SCHEMBL14992018 | 0.86 | CYP11B2 (0.76) | CYP11B2CYP11B1 | |
| SCHEMBL14992141 | 0.83 | CYP11B2 (0.71) | CYP11B2CYP11B1 | |
| SCHEMBL14991451 | 0.81 | CYP11B2 (0.69) | CYP11B2CYP11B1 | |
| SCHEMBL14992443 | 0.80 | CYP11B2 (0.66) | CYP11B2CYP11B1 | |
| SCHEMBL14991507 | 0.79 | CYP11B2 (1.00) | CYP11B2CYP11B1TSHR | |
| SCHEMBL14991538 | 0.77 | CYP11B2 (0.63) | CYP11B2CYP11B1ALDH1A1 | |
| SCHEMBL14991623 | 0.77 | CYP11B2 (0.81) | CYP11B2CYP11B1TSHRALDH1A1 | |
| SCHEMBL14991663 | 0.76 | CYP11B2 (1.00) | CYP11B2CYP11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2785695-B1 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-06-17 | — | — | EP | claimed |
| US-9133158-B2 | Bicyclic dihydroisoquinoline-1-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2015-09-15 | — | — | US | claimed |
| EP-2785695-A1 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-08 | — | — | EP | claimed |
| US-20130143863-A1 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-06-06 | — | — | US | claimed |
| WO-2013079452-A1 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-06 | — | — | WO | claimed |
| EP-2785695-B1 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-06-17 | — | — | EP | disclosed |
| US-9133158-B2 | Bicyclic dihydroisoquinoline-1-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133158-B2 | Bicyclic dihydroisoquinoline-1-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133158-B2 | Bicyclic dihydroisoquinoline-1-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2785695-A1 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-08 | — | — | EP | disclosed |
| US-20130143863-A1 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130143863-A1 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130143863-A1 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2013079452-A1 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013079452-A1 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143863-A1 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES | CYP11B1, CYP11B2, HSD11B1 | CYP11B2 2/4885CYP11B1 1/4885TSHR 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.